Ocugen – Consensus Indicates Potential 9.2% Upside

Broker Ratings

Ocugen found using ticker (OCGN) have now 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 8 and 0.7 with the average target price sitting at 3.55. Now with the previous closing price of 3.25 this would imply there is a potential upside of 9.2%. The 50 day moving average now sits at 2.31 while the 200 day moving average is 0.81. The market capitalisation for the company is $851m. Find out more information at: http://www.ocugen.com

Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index